

Figure S1 Flowchart of the study.






Figure S2 The postoperative pathological downstaging rate of TNM stage and N stage.

B



**Figure S3** Kaplan-Meier survival curves of all participants.



**Figure S4** Kaplan-Meier survival curves according to the stage and PD-L1 TPS level. (A) Progression-free survival comparisons: PD-L1 TPS  $\geq 50\%$  vs. PD-L1 TPS  $< 50\%$ ; (B) overall survival comparisons: PD-L1 TPS  $\geq 50\%$  vs. PD-L1 TPS  $< 50\%$ ; (C) progression-free survival comparisons: stage IB-IIB vs. stage IIIA-IIIIB; (D) overall survival comparisons: stage IB-IIB vs. stage IIIA-IIIIB. PD-L1, programmed death-ligand 1; TPS, tumor proportion score; HR, hazard ratio.

**Table S1** Immunotherapy and chemotherapy drugs and treatment regimens

Chemotherapy/immunotherapy	Camrelizumab	Pembrolizumab	Tislelizumab	Sintilimab	Nivolumab	Toripalimab	Durvalumab
Paclitaxel-albumin	44	52	15	10	5	2	0
Pemetrexed	2	11	1	2	2	0	0
Docetaxel	1	3	0	1	0	0	0
Gemcitabine	0	2	0	0	0	0	1
Paclitaxel	0	0	2	0	0	0	0
Liposome paclitaxel	0	2	0	0	0	0	0

**Table S2** Adjuvant treatment

Patients receiving adjuvant treatment <sup>a</sup>	N (%)
Any	36 (22.8)
Chemotherapy	18 (11.4)
Radiotherapy <sup>b</sup>	5 (3.2)
Immunotherapy <sup>c</sup>	29 (18.4)
Targeted therapy	6 (3.8)

<sup>a</sup>, patients may have received more than one type of subsequent therapy; <sup>b</sup>, patients with risk factors such as N2 station lymph node metastasis who could not tolerate adjuvant chemotherapy or immunotherapy were advised to undergo adjuvant radiotherapy; <sup>c</sup>, most patients with adjuvant immunotherapy were suggested to take up to 1 year, and partial patients with pCR may be recommended to shorten it to 6 months.

**Table S3** Postoperative adverse events

Adverse events	Grade 2-4, N (%)	Grade 5, N (%)
Blood loss >400 mL	18 (11.4)	0
Pneumonia	4 (2.5)	3 (1.9)
Chylothorax	3 (1.9)	0
Respiratory failure	2 (1.3)	1 (0.6)
Pulmonary embolism	1 (0.6)	0